Sprint Bioscience AB (publ)
SSE:SPRINT.ST
Overview | Financials
Company Name | Sprint Bioscience AB (publ) |
Symbol | SPRINT.ST |
Currency | SEK |
Price | 0.876 |
Market Cap | 61,162,408 |
Dividend Yield | 0% |
52-week-range | 0.451 - 3.28 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Mathias Skalmstad |
Website | https://www.sprintbioscience.com |
An error occurred while fetching data.
About Sprint Bioscience AB (publ)
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD